Verrica Pharmaceuticals Inc (OQ:VRCA)

Business Focus: Pharmaceuticals

Mar 07, 2019 16:01 ET
Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced...
Mar 02, 2019 17:10 ET
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today presented data...
Feb 27, 2019 07:00 ET
Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Feb 12, 2019 07:00 ET
Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced that results from two...
Jan 07, 2019 07:00 ET
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Jan 03, 2019 06:30 ET
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Nov 16, 2018 08:40 ET
Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PlayAGS, Inc. (NYSE:AGS), BEST, Inc. Sponsored ADR (NYSE:BSTI), Verrica...
Nov 07, 2018 16:32 ET
Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Nov 01, 2018 16:05 ET
Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Sep 24, 2018 07:05 ET
Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® Indexes
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Sep 12, 2018 16:05 ET
Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Aug 15, 2018 06:50 ET
Verrica Appoints Neetu Dhaliwal as Vice President of Business Development
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Aug 07, 2018 16:01 ET
Verrica Reports Second Quarter 2018 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Jun 19, 2018 16:05 ET
Verrica Pharmaceuticals Inc. Announces Closing of Initial Public Offering
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Jun 14, 2018 17:52 ET
Verrica Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...